Archive

ASCO Daily News Archive

The ASCO Daily News is the official news source for the ASCO Annual Meeting, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.

June 13, 2017

A meta-analysis of three randomized clinical trials fails to support use of selective internal radiotherapy in combination with first-line oxaliplatin and fluorouracil chemotherapy in patients with liver-only and liver-dominant metastatic colorectal cancer.

Read more
June 13, 2017

Dr. Maura L. Gillison, who presented the findings, also presented a minimum 11.4-month follow-up analysis of CheckMate 141 for the overall patient population in the study to update the previous 2.2-month follow-up findings.

Read more
June 13, 2017

The results of a global phase III trial, suggest that alectinib, an ALK tyrosine-kinase inhibitor, leads to greater PFS and longer duration until CNS progression in patients with untreated, advanced ALK-positive non–small cell lung cancer compared with crizotinib.

Read more
June 13, 2017

A follow-up study of the RESONATE phase III trial provides further support that ibrutinib, an inhibitor of Bruton tyrosine kinase, achieves greater PFS than ofatumumab, a high OS rate, and high tolerability among patients with CLL who have had at least one prior treatment.

Read more
June 13, 2017

Personalized immunotherapy coupled with “concerned and focused translational efforts” will continue to expand the knowledge base in head and neck cancer research.

Read more
June 13, 2017

Six months of adjuvant chemotherapy yielded superior disease-free survival compared with 3 months in patients with stage III colon cancer but also caused significantly more toxicity.

Read more
June 13, 2017

Results of the large Italian TOSCA trial narrowly failed to meet the primary endpoint but still offer great value to patients with high-risk stage II or stage III colon cancer slated to receive oxaliplatin-based treatment after surgery.

Read more
June 13, 2017

A large trial found that 3 months of adjuvant chemotherapy was noninferior to 6 months for patients with high-risk stage II or stage III colon or rectal cancer. This finding was true for the CAPOX regimen but not for FOLFOX.

Read more
June 6, 2017

Dr. Druker, who was instrumental in the development of imatinib, highlighted the hurdles he faced in bringing the tyrosine-kinase inhibitor to market, particularly the skepticism from others in the field who were sure that a single-agent therapy for cancer would never work.

Read more
June 6, 2017

Carl H. June, MD, of the University of Pennsylvania, accepted the 2017 David A. Karnofsky Memorial Award and Lecture on June 3, an honor bestowed for his pioneering work on engineering T cells in targeted cancer therapy.

Read more

June 6, 2017

Researchers presented results of four studies evaluating new approaches to targeted therapies for patients with lung cancer, including metastatic non–small cell lung cancer.

Read more
June 6, 2017

In contrast to more common cancers, some sarcoma subsets are fairly rare and standard treatments have not been established. However, for each sarcoma type discussed, strategies are being developed with the aim of improving outcomes for patients with sarcoma.

Read more

June 5, 2017

Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to chemotherapy and trastuzumab.

Read more
June 5, 2017

Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.

Read more
June 5, 2017

The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.

Read more
June 5, 2017

Results from two separate trials suggest that lenalidomide can induce deeper and longer remission in patients with multiple myeloma when used as part of induction and maintenance therapy.

Read more
June 5, 2017

The PD-L1 inhibitor pembrolizumab continued to demonstrate an overall survival benefit compared with chemotherapy among patients with advanced urothelial cancer with no new safety signals.

Read more
June 5, 2017

The safety and efficacy of trastuzumab biosimilars for neoadjuvant breast cancer therapy demonstrated comparable safety and efficacy, according to two studies.

Read more
June 5, 2017

Results from the Short-HER study suggest a shorter course may reduce the rate of severe cardiac toxicity.

Read more
June 4, 2017

Although new discoveries regarding the biology of sarcoma are occurring at a historic pace, novel drug development in this rare cancer is complicated by the heterogeneous nature of disease.

Read more